Eli Lilly has introduced a new initiative aimed at increasing employer coverage for obesity medications in the United States, addressing a significant barrier to treatment access for patients. This program comes at a time when both Lilly and its competitor, Novo Nordisk, are reducing the out-of-pocket costs for their popular obesity treatments—Zepbound and Mounjaro, which retail for over $1,000 monthly. However, many employers remain hesitant to provide this coverage due to high costs, leaving about half of those with commercial insurance unable to access the treatments.
As of October, a survey found that nearly 20% of firms with more than 200 employees and 43% of those with over 5,000 workers offer coverage for GLP-1 drugs used for weight loss. Kevin Hern, senior vice president at Lilly, noted that this new “Employer Connect” platform aims to give employers more flexibility in monitoring their expenses while expanding access to these medications for employees.
Under this platform, employers can opt for a discounted price of $449 per month for a multi-dose version of Zepbound. The program addresses core concerns for employers, such as drug price transparency and customized benefits design through collaboration with various independent administrators. By utilizing more than 15 different program administrators, employers can tailor their obesity treatment offerings to meet specific workforce needs, including comprehensive management solutions like telehealth and nutritional support.
Lilly intends to grow its list of program administrators further. Additionally, upcoming changes will allow Medicare recipients easier access to obesity medications as part of agreements made during the Trump administration.
Why this story matters:
- Expands treatment access for obesity, a significant public health issue.
Key takeaway:
- Employers have new options to provide coverage for obesity drugs, potentially reducing barriers for patients.
Opposing viewpoint:
- Some employers may still resist offering coverage due to lingering cost concerns and the complexity of managing benefit plans.
